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Abstract 
Human Brucellosis still challenges many physicians, especially in developing countries where it is still a very 
common, but sometimes ignored disease. Its reemergence in developed countries and its status as a class B 
bioterrorist agent has recently attracted much interest. Having over 500,000 new cases annually, Brucellosis is 
known as one of the most common zoonotic infections in the world and “the great imitator” because of many 
clinical and hematological manifestations. Brucellosis is still endemic in many developing countries and remains 
under-diagnosed and sometimes missed reported. Although this province (Kurdistan, Iran) is a Brucella endemic 
area with a very high prevalence and incidence rate, except for very few and negligible case reports, we did not 
find any reports or epidemiological study regarding this zoonotic infection. This is the first reported case of 
Brucellosis with pancytopenia from this western province of Iran which has been neglected. Our case was a 16-
year-old girl referred with protracted fever during the last month and undetermined diagnosis. She also suffered 
from generalized pain, pale skin, sweating, anorexia, and weight loss. After clinical surveying, taking history, and 
physical examination, Brucella infection was suspected. Diagnosis confirmed by standard tube agglutination test 
(STA), 1/640. The patient was successfully treated with doxycycline, rifampicin, and ceftriaxone. 
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Introduction1 
Brucellosis or Malta fever is the most common 
zoonotic infection in the globe caused by a gram-
negative, non-motile, facultative intracellular 
bacterium that belongs to the genus of Brucella.1 
It affects animals like sheep, goats, cattle, and 
pigs as the primary host and humans as the 
secondary.2 It is still a common health problem 
in some Middle Eastern and Mediterranean 
countries including Iran.3 Over the last ten years, 
the infection has re-emerged especially in 




Eastern Europe, the Balkans, and Eurasia. 
Brucellosis, although almost eradicated in many 
parts of the world, still remains widespread and 
endemic in developing countries.4 It is very 
contagious for humans and the disease, unless 
diagnosed and treated both promptly and 
effectively, can become chronic, affecting 
multiple body systems.5 The World Health 
Organization (WHO) has designated Brucellosis 
as a historically “neglected” zoonosis.1 
In desirable situations and strong health 
systems less than 1 out of 8 Brucellosis case is 
diagnosed in opportune and reported.1 While 
basic science and epidemiology of human 
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and overlooked, therefore highlighting its status 
in endemic area and reporting rare cases may 
attract global attention.6 
Kurdistan province of Iran is an endemic 
region of Malta fever with a very high 
prevalence and incidence rate.3 Unfortunately no 
comprehensive and reliable epidemiological 
report from this area is available. So, in addition 
to case report, an estimation of this neglected 
important zoonotic infection in this province is 
presented. 
Case Report 
A 16-year-old girl referred to our university 
hospital from a rural clinic presented with 
prolonged fever and undetermined diagnosis. 
She suffered from generalized pain, pale skin, 
sweating, anorexia and weight loss over the 
previous one month. Physical examination 
showed fever (39o C), splenomegaly without 
hepatomegaly and lymphadenopathy. 
In laboratory test results, hemoglobin (Hb), 
hematocrit (Hct), leukocytes and platelets count 
were decreased significantly. Laboratory 
analysis on the admission day showed 
leukopenia (white blood cell count = 3000/mm3), 
thrombocytopenia (Plt = 35,000), and anemia 
(Hb = 7.72 g/dl, Hct = 26.02%). Evaluation of the 
peripheral blood smear (PBS) revealed 
neutrophils = 61%, lymphocytes = 27%, and 
eosinophils = 2%. The blood smear was also 
positive for anisocytosis, poikilocytosis, and 
hypochromia. Both urine and blood cultures 
were negative for pathogenic bacterial infections. 
The erythrocyte sedimentation rate and  
C-reactive protein (CRP) were 12 mm/1 h and 
3+, respectively. The biochemical tests revealed 
an increase in the alanine aminotransferase 
(ALT) 149 U/l (normal range is 5-40), and 
aspartate aminotransferase (AST) 174 U/l 
(normal range is 5-40). The other laboratory 
results were within normal ranges.  
Because of pancytopenia and weight loss, 
hematological malignancies were suspected. 
Normal erythroid and myeloid maturation in 
bone marrow aspiration ruled out an 
underlying malignancy. On the other hand, 
because of abnormal AST and ALT liver 
involvement was obvious. Although both urine 
and blood cultures were negative and white 
blood cells (WBC) count was decreased, 
protracted bacterial fever or viral infections 
were under discussion. At last, Malta fever and 
Typhoid fever were under suspicion. 
Antibodies against typhoid fever were only 
positive for O and H antigens at titer 1/80. 
However, standard tube agglutination (STA) for 
Brucella species was positive at a titer of 1/640.  
Therefore, according to the clinical and 
laboratory findings treatment for Brucellosis was 
started and patient was administered doxycycline 
100 mg orally twice daily, rifampicin 450 mg 
orally once daily, and ceftriaxone 4 g/day 
intravenously (all for eight weeks).7 By the fifth 
day of the treatment, her fever subsided and 
hematological findings improved (Hb = 9.1 g/dl, 
Ht = 28.4%, Plt = 78000/mm3, WBC = 2300/mm3, 
neutrophils = 40%, lymphocytes = 59%, 
eosinophils 1%). PBS was still positive for 
anisocytosis, poikilocytosis and hypochromia. 
The patient discharged from the hospital with 
the recommendation of ceftriaxone and 
rifampicin. After 8 weeks of treatment, all 
hematological parameters were within normal 
ranges and on later follow up samples showed 
no evidence of Brucella seropositivity. 
Discussion 
Malta fever is a systemic infection caused by 
Brucella species. These bacteria transmit from 
animals to humans and colonize in different body 
tissues, dominantly in lymphoreticular system.8 
Main reason for reporting this case is to advise 
physicians to consider Brucella infection in febrile 
patient who present with pancytopenia in the 
endemic areas, knowing that health education 
especially to villagers about routs of transmission, 
prevention methods, food supply, and delivery 
supervision could decrease the prevalence of the 
disease. The disease has a high morbidity and a 
broad spectrum of clinical manifestations ranging 
from asymptomatic disease to severe and/or fatal 
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illness.2 As it is one of the leading infections 
causing fever of unknown origin, it can mimic 
those of other febrile illnesses.9 The incubation 
period is usually one to four weeks.8 
Hematological abnormalities include anemia, 
leukopenia, thrombocytopenia, pancytopenia, 
bleeding diathesis, and coagulation disorders, 
such as disseminated intravascular coagulation 
(DIC). Up to 87.5% of patients with pancytopenia 
induced by Brucella infection have positive blood 
cultures and almost all of them had positive 
Brucella antibody.8 
Brucellosis is notorious for relapsing even after 
adequate treatment.10 Relapse usually occurs 
within the first six months following completion 
of treatment. Causes of relapse include 
inadequate choice of antibiotics, shortened 
treatment duration, lack of adherence, or 
localized foci of infection. Relapse due to 
antibiotic resistance is rare;10 hence, significant of 
its prompt and proper management. 
Due to evading immune system and tendency 
to relapse, its eradication is very difficult.2 
Physicians in endemic areas always say 
“everything can be Malta fever until proven 
different”.1 Non-specific complications may 
initially lead clinicians to a differential diagnosis 
other than Brucella.9 Hematologic complications 
during the course of Brucellosis, with numerous 
patterns of cytopenia or lymphocytosis has been 
reported.11 However, one should always take 
into account the postscript to the above-
mentioned rule, which says that “in endemic 
areas everything can be Brucellosis, but 
Brucellosis is not the only possible diagnosis.” 
This has been demonstrated in some studies 
where hematologic complications that might 
have been attributed to concurrent. Brucellosis 
was actually due to underlying undiagnosed 
hematologic malignancies.8,12 
In our case, in spite of living in a rural endemic 
area of Brucellosis and having a positive history 
of consumption of un-pasteurized dairy products, 
unfortunately there was no early diagnostic 
suspicion of Brucellosis and the patient suffered 
from a prolonged fever. Her family also tended as 
a shepherd. Although anemia in Brucellosis is 
expected due to bone marrow involvement, 
numerous other pathogenic mechanisms can be 
implicated.10 
Brucellosis is a notifiable disease, yet its cases 
remain often unrecognized and underestimation; 
reflecting inadequacy of diagnostic laboratory 
services in most of the endemic area, especially 
un-developed countries.13 The geographical 
pattern of this zoonotic infection is constantly 
changing.14 The causes of its re-emergence and 
recent increase in the incidence of Brucellosis 
including socioeconomic changes, wars and 
political turbulence in some countries, 
inadequate control programs in un-developed 
countries, ease of human international travel 
recently, uncontrolled animal transportation 
across open borders, and at last Brucellosis is a 
complex disease that has different cycles of 
expansion and regression.13,15 
Brucella bacteremia may be complicated by: 
infective endocarditis, fatal endotoxic shock that 
may be associated with DIC, multiorgan failure, 
microangiopathic hemolytic anemia (MAHA) 
with bleeding tendency and pancytopenia and 
death.2 Despite the severity of these 
complications, the early use of appropriate 
antimicrobial therapy usually leads not only to 
clinical improvement but also to normalization 
of the hematological parameters and the 
coagulation profile.9 
On a few occasions, Brucellosis has been 
encountered in patients with acute leukemia and 
solid tumors.1,2 As reported cases of Brucellosis 
developed in patients with malignant disorders 
living in countries that are endemic for this 
infection, the dominant presenting features of 
Brucellosis were febrile neutropenia and 
pancytopenia.2 
Kurdistan province of Iran with a population 
of 1.5 million people is an endemic region of 
Malta fever with a very high prevalence and 
incidence rate.3 According to the statistics of 
Iranian Ministry of Health, in 2012 the incidence 
rate was 50/100000 (unpublished data). But 
upon over 15 years’ experience of Brucella 
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treatment in this endemic area, it is obvious that 
its real burden is much higher, maybe over  
10 times, i.e. 500/100000 new cases annually. 
Miss diagnosis, overlook, and finally and failure 
in reporting are the main reasons for 
mismanagement of the disease. 
In conclusion, physicians should have a high 
index of suspicion regarding Malta fever when 
evaluating patients presenting with prolonged 
pyrexia, pancytopenia, and a history risk of 
consumption of non-pasteurized dairy 
products. 
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